SCHEMBL112699

SCHEMBL112699

COC(=O)c1cnc(Cl)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.43
CES1 P23141 1/20 0.43
HTT P42858 2/20 0.42
MAPT P10636 2/20 0.41
KMT2A Q03164 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 5/20 0.39
MAPK1 P28482 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.37
HSP90AA1 P07900 1/20 0.37
RAB9A P51151 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111232 0.80 NLRP3 (0.46) HTTMAPTCYP1A2CYP2C19ALDH1A1
SCHEMBL15057751 0.78 MAPT (0.46) FAAHCES1HTTMAPTKMT2A
SCHEMBL12939836 0.78
SCHEMBL7923464 0.77 FAAH (0.43) FAAHCES1HTTMAPTKMT2A
SCHEMBL21525621 0.77 FAAH (0.43) FAAHCES1HTTMAPTKMT2A
SCHEMBL7977655 0.75
SCHEMBL24339596 0.74 FAAH (0.52) FAAHCES1HTTMAPTKMT2A
SCHEMBL31598644 0.73 KDM4E (0.42) FAAHCES1HTTMAPTKMT2A
SCHEMBL31589410 0.73 KDM4E (0.42) FAAHCES1HTTMAPTKMT2A
SCHEMBL22437171 0.73 FAAH (0.40) FAAHCES1HTTMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479827-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-11-25 US disclosed
CN-116120287-B Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein 勃林格殷格翰国际有限公司 2025-01-28 CN disclosed
US-20240076286-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-03-07 US disclosed
US-20240002363-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-01-04 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
CN-116120287-A Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein 勃林格殷格翰国际有限公司 2023-05-16 CN disclosed
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PROXIMAGEN LLC (US) 2023-04-13 US disclosed
EP-4103562-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS Boehringer Ingelheim International GmbH (DE) 2022-12-21 EP disclosed
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN, LLC (US) 2022-11-29 US disclosed
CN-115052873-A Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors 勃林格殷格翰国际有限公司 2022-09-13 CN disclosed
WO-2010125082-A1 OXAZOLE SUBSTITUTED INDAZOLES AS PI3-KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO disclosed
US-20100280045-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-11-04 US disclosed
US-20100280029-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-11-04 US disclosed
EP-2019822-B1 A NEW PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS AB SCIENCE (FR) 2010-09-08 EP disclosed
WO-2010052199-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-14 WO disclosed
US-20100120874-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS HOFFMANN-LA ROCHE, INC. 2010-05-13 US disclosed
US-20100120874-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS HOFFMANN-LA ROCHE, INC. 2010-05-13 US disclosed
US-20090192317-A1 PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS AB SCIENCE (FR) 2009-07-30 US disclosed
EP-2019822-A1 A NEW PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS AB Science (FR) 2009-02-04 EP disclosed
WO-2007131953-A1 A NEW PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS AB SCIENCE (FR) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PNPO, XDH, EPX FAAH 4642/4885CES1 1424/4885HTT 3781/4885
US-12479827-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 FAAH 162/4885CES1 198/4885HTT 3536/4885
US-20100120874-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS BACE1, APH1A, APP FAAH 591/4885CES1 1675/4885HTT 88/4885
US-20100280045-A1 NOVEL COMPOUNDS PLK3, PLK1, PLK2 FAAH 2881/4885CES1 1102/4885HTT 4008/4885
US-20100280029-A1 NOVEL COMPOUNDS PIK3CD, PIK3CA, PIK3C2B FAAH 3113/4885CES1 1054/4885HTT 3650/4885
US-20090192317-A1 PROCESS FOR THE SYNTHESIS OF 2-AMINOXAZOLE COMPOUNDS ABL1, FLT3, ABL2 FAAH 4615/4885CES1 2233/4885HTT 4422/4885
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PNPO, XDH, EPX FAAH 4642/4885CES1 1424/4885HTT 3781/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 FAAH 162/4885CES1 198/4885HTT 3536/4885
US-20240002363-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 FAAH 162/4885CES1 198/4885HTT 3536/4885
US-20240076286-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 FAAH 162/4885CES1 198/4885HTT 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.